Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 1 / 2 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerTreatment